Thyroid dysfunction after mantle irradiation of Hodgkin's disease patients

SUMMARY Thyroid dysfunction can develop in patients with Hodgkin's disease who are treated with mantle irradiation. During the period 1970‐89, the records of 320 patients who received mantle irradiation and who had thyroid function tests (TFT) were retrospectively reviewed. The median age was 30 years (range, 7‐69 years). The median mantle and thyroid dose was 36 Gy (range, 30‐40 Gy) and 39.8 Gy (range, 32‐65 Gy), respectively. Overall thyroid dysfunction was present in 39% of the patients. Clinical hypothyroidism was seen in 10% and biochemical hypothyroidism was noted in 25%. Hyperthyroidism was found in 4% of patients. Thyroid nodules had developed in six patients (2%), of which those in four patients were malignant. Age, sex, histological subtype, stage of disease, dose, lymphangiogram and treatment with chemotherapy were not significant factors in the development of thyroid dysfunction. The narrow dose range prevented adequate analysis of dose effect. The results indicate that the incidence of thyroid abnormalities is high enough to warrant regular TFT assessment with pre‐irradiation levels and follow‐up testing for life because the development of abnormalities can occur many years later. Thyroid examination should form part of the routine follow‐up examination and any abnormality should be promptly investigated.